Resverlogix RVXCF Stock
Resverlogix Price Chart
Resverlogix RVXCF Financial and Trading Overview
| Resverlogix stock price | 0.06 USD |
| Previous Close | 0.08 USD |
| Open | 0.08 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.08 - 0.08 USD |
| 52 Week Range | 0.08 - 0.27 USD |
| Volume | 17K USD |
| Avg. Volume | 85.74K USD |
| Market Cap | 21.67M USD |
| Beta (5Y Monthly) | 0.633477 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RVXCF Valuation Measures
| Enterprise Value | 72.02M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.568 |
Trading Information
Resverlogix Stock Price History
| Beta (5Y Monthly) | 0.633477 |
| 52-Week Change | -57.89% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.27 USD |
| 52 Week Low | 0.08 USD |
| 50-Day Moving Average | 0.1 USD |
| 200-Day Moving Average | 0.12 USD |
RVXCF Share Statistics
| Avg. Volume (3 month) | 85.74K USD |
| Avg. Daily Volume (10-Days) | 13.35K USD |
| Shares Outstanding | 267.8M |
| Float | 176.27M |
| Short Ratio | N/A |
| % Held by Insiders | 44.27% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -78.97% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -10965000 USD |
| Net Income Avi to Common (ttm) | -3610000 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 40K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 50.19M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.127 |
| Book Value Per Share (mrq) | -0.223 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3541000 USD |
| Levered Free Cash Flow (ttm) | 599.63K USD |
Profile of Resverlogix
| Country | United States |
| State | AB |
| City | Calgary |
| Address | 4820 Richard Road SW |
| ZIP | T3E 6L1 |
| Phone | 403-254-9252 |
| Website | https://www.resverlogix.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
Q&A For Resverlogix Stock
What is a current RVXCF stock price?
Resverlogix RVXCF stock price today per share is 0.06 USD.
How to purchase Resverlogix stock?
You can buy RVXCF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Resverlogix?
The stock symbol or ticker of Resverlogix is RVXCF.
Which industry does the Resverlogix company belong to?
The Resverlogix industry is Biotechnology.
How many shares does Resverlogix have in circulation?
The max supply of Resverlogix shares is 287.34M.
What is Resverlogix Price to Earnings Ratio (PE Ratio)?
Resverlogix PE Ratio is now.
What was Resverlogix earnings per share over the trailing 12 months (TTM)?
Resverlogix EPS is -0.03 USD over the trailing 12 months.
Which sector does the Resverlogix company belong to?
The Resverlogix sector is Healthcare.